pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,882 catalysts · 5,256 phase readout · 2,308 8k filing · 315 pdufa · 259 earnings · 2 approval · 1 adcom

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 0 catalysts2026-07-28: 0 catalysts2026-07-29: 0 catalysts2026-07-30: 37 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 13 catalysts2026-08-05: 16 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 1 catalyst2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 1 catalyst2026-10-22: 2 catalysts2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout5,256
  • 8k filing2,308
  • pdufa315
  • earnings259
  • approval2
  • adcom1
therapy area

no tagged catalysts yet

Date TBD

50
›RECRUITINGphase readoutNCT07142590: Determination of Iron Absorption and Losses in People Living at High Altitude to Investigate the Requirements in This Population Group Using a Newly Developed Technique

Sponsor: Diego Moretti. Phase: NA. Conditions: Iron Absorption, Iron Requirements, Altitude

full page →ctgov ↗
›RECRUITINGphase readoutNCT07244510: Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa

Sponsor: Sinocelltech Ltd.. Phase: PHASE2. Conditions: Hidradenitis Suppurativa (HS)

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT04317820: Deep Brain Reorienting in Post-traumatic Stress Disorder

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Phase: NA. Conditions: PTSD, Post-traumatic Stress Disorder

full page →ctgov ↗
›RECRUITINGphase readoutNCT06778382: Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.

Sponsor: Shandong Cancer Hospital and Institute. Phase: PHASE2. Conditions: Colorectal Neoplasms Malignant

full page →ctgov ↗
›RECRUITINGphase readoutNCT05571059: Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Sponsor: Cumberland Pharmaceuticals. Phase: PHASE2. Conditions: Idiopathic Pulmonary Fibrosis

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06443359: Hypofractionated Regional Nodal Irradiation in Breast Cancer

Sponsor: Corewell Health East. Phase: NA. Conditions: Breast Cancer

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05081180: Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Sponsor: EMD Serono Research & Development Institute, Inc.. Phase: PHASE1. Conditions: Central Nervous System Tumors

full page →ctgov ↗
›COMPLETEDphase readoutNCT06685146: The Glucose-Independent Effects of Exogenous Glucagon on Insulin Secretion and Cognitive Function in Healthy Subjects

Sponsor: Nicolai Jacob Wewer Albrechtsen. Phase: NA. Conditions: Glucose Metabolism, Insulin Secretion

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07533227: Intestinal Microbiota Transplantation for Treating Advanced Tumor Cachexia

Sponsor: Hua Jiang. Phase: PHASE2. Conditions: Cachexia; Cancer, Fecal Microbiota Transplantation (FMT)

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06714461: A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia

Sponsor: Sanofi. Phase: . Conditions: Rheumatoid Arthritis, Psoriatic Arthritis

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06415461: A Study Assessing the Safety of Cord Blood Product in Sacroiliac Joint Syndrome (SIJ)

Sponsor: University of Florida. Phase: PHASE1. Conditions: Sacroiliac; Backache, Pain, Back

full page →ctgov ↗
›RECRUITINGphase readoutNCT07021742: BioHealx® Anal Fistula Device Post Market Surveillance Study

Sponsor: Signum Surgical USA Inc.. Phase: . Conditions: Fistula-in-ano

full page →ctgov ↗
›COMPLETEDphase readoutNCT05045742: Prediction of Patient Deterioration Using Machine Learning

Sponsor: Brigham and Women's Hospital. Phase: . Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased

full page →ctgov ↗
›COMPLETEDphase readoutNCT07480642: Caregiver Burden and Psychological Outcomes in Caregivers of Stroke Patients With Lower Urinary Tract Symptoms

Sponsor: Gaziler Physical Medicine and Rehabilitation Education and Research Hospital. Phase: . Conditions: Stroke, Fatigue Syndrome, Chronic, Caregiver

full page →ctgov ↗
›COMPLETEDphase readoutNCT07343973: Post-Market Study on the Safety and Effectiveness of the OpHLINE OVD in Cataract Surgery

Sponsor: i+Med S.Coop.. Phase: NA. Conditions: Cataract Surgery

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07551973: The Effect of an ARCS Model-Based Escape Room Simulation on Nursing Students' Knowledge, Motivation, and Self-Efficacy Regarding Surgical Site Infections

Sponsor: Ankara Yildirim Beyazıt University. Phase: NA. Conditions: Surgical Site Infections, ARSC Motivation Model, Escape Room Simulation

full page →ctgov ↗
›RECRUITINGphase readoutNCT06983041: Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)

Sponsor: Coologics, Inc. Phase: NA. Conditions: Vulvovaginal Candidiasis (VVC), Yeast Vaginitis

full page →ctgov ↗
›RECRUITINGphase readoutNCT07280741: Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators

Sponsor: University of Sao Paulo General Hospital. Phase: PHASE4. Conditions: Autoimmune Rheumatic Diseases

full page →ctgov ↗
›COMPLETEDphase readoutNCT00144794: Mucopolysaccharidosis I (MPS I) Registry

Sponsor: Genzyme, a Sanofi Company. Phase: . Conditions: Mucopolysaccharidosis I (MPS I)

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07538817: ORI MONITORING IN LOW AND NORMAL FLOW ANESTHESIA APPLICATIONS

Sponsor: Başakşehir Çam & Sakura City Hospital. Phase: . Conditions: HYPEROXY, OXYGEN RESERVE INDEX

full page →ctgov ↗
›COMPLETEDphase readoutNCT04301089: Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients

Sponsor: National Cancer Institute (NCI). Phase: PHASE2. Conditions: Anxiety

full page →ctgov ↗
›RECRUITINGphase readoutNCT07480889: Effect of Adding a Low-Dose Epinephrine Bolus Prior to Infusion on Maternal Hemodynamic Stability During Cesarean Section

Sponsor: Cairo University. Phase: PHASE3. Conditions: Hemodynamic (MAP) Stability

full page →ctgov ↗
›COMPLETEDphase readoutNCT05858489: Concordance Between Mini-Mental Stats Examination (MMSE) and an Adapted Version of the MMSE in Reunion Island Population (MMS-Run)

Sponsor: Centre Hospitalier Universitaire de la Réunion. Phase: . Conditions: Neurocognitive Deficit

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT06287450: A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults

Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd. Phase: PHASE1. Conditions: Respiratory Syncytial Virus Infections

full page →ctgov ↗
›RECRUITINGphase readoutNCT07557550: Comparison of Two Relaxation Strategies Between Glasses, Virtual Reality Headset, and Without Relaxation Tool, in the Anxiety Preoperative of Orthopedic Adult Patients

Sponsor: Centre Hospitalier Universitaire, Amiens. Phase: NA. Conditions: Relaxation, Virtual Reality, Anxiety Preoperative

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07438405: An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease

Sponsor: Amgen. Phase: PHASE2. Conditions: Thyroid Eye Disease

full page →ctgov ↗
›TERMINATEDphase readoutNCT00880594: Irritable Bowel Syndrome (IBS) Functional Magnetic Resonance Imaging (fMRI) With Desipramine

Sponsor: Washington University School of Medicine. Phase: NA. Conditions: Irritable Bowel Syndrome

full page →ctgov ↗
›COMPLETEDphase readoutNCT07058194: Effect of Pre- and Postoperative ESP Block on Frontal QRS-T Angle in Laparoscopic Cholecystectomy

Sponsor: Harran University. Phase: NA. Conditions: Cholecystectomy, Laparoscopic, Pain, Postoperative, Electrocardiography, Regional Anesthesia, Cardiac Electrophysiology

full page →ctgov ↗
›RECRUITINGphase readoutNCT07193394: Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

Sponsor: Institut Curie. Phase: PHASE2. Conditions: Metastatic Breast Cancer ( HER2 Negative), Unresectable Breast Cancer

full page →ctgov ↗
›RECRUITINGphase readoutNCT04728022: Brain Research Apprenticeships in New York at Columbia

Sponsor: Columbia University. Phase: NA. Conditions: Educational Activities

full page →ctgov ↗
›RECRUITINGphase readoutNCT06205953: A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia. Phase: . Conditions: AL Amyloidosis

full page →ctgov ↗
›RECRUITINGphase readoutNCT06922045: Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

Sponsor: Jiangsu BioJeTay Biotechnology Co., Ltd.. Phase: PHASE3. Conditions: Hemophilia

full page →ctgov ↗
›RECRUITINGphase readoutNCT06704672: Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus

Sponsor: Hoffmann-La Roche. Phase: NA. Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

full page →ctgov ↗
›RECRUITINGphase readoutNCT04494672: A Study to Verify if the Surgery for the Proximal Femur Fracture Can be Improved With the Help of a Navigation System

Sponsor: Christian Candrian. Phase: NA. Conditions: Femoral Fracture

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07528872: Serum COMP and MMP-3 in Knee Osteoarthritis

Sponsor: Kanuni Sultan Suleyman Training and Research Hospital. Phase: . Conditions: Knee Osteoarthritis

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07385872: Performance of a Novel Concept for Internal Fixation of a Novel Peripheral Nerve Block Catheter

Sponsor: Nordsjaellands Hospital. Phase: NA. Conditions: Primary Condition: Nerve Block, Secondary Condition: Catheter Displacement, Focus of Study: Sciatic Nerve

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06015672: Accelerated TMS for Focal Hand Dystonia

Sponsor: Duke University. Phase: NA. Conditions: Isolated Focal Hand Dystonia

full page →ctgov ↗
›COMPLETEDphase readoutNCT06229795: Effect of Green Tea on Obese Pediatrics With Prediabetes

Sponsor: Ain Shams University. Phase: PHASE3. Conditions: PreDiabetes

full page →ctgov ↗
›COMPLETEDphase readoutNCT07360795: Do We Really Bleed in Percutaneous Nephrolithotomy? A Single-Surgeon, Single-Center Experience

Sponsor: Elazıg Fethi Sekin Sehir Hastanesi. Phase: . Conditions: Urolithiasis

full page →ctgov ↗
›RECRUITINGphase readoutNCT05397639: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Sponsor: Suven Life Sciences Limited. Phase: PHASE3. Conditions: Agitation, Alzheimer's Type Dementia

full page →ctgov ↗
›RECRUITINGphase readoutNCT04788277: Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)

Sponsor: Thomas Jefferson University. Phase: . Conditions: Prostate Carcinoma

full page →ctgov ↗
›RECRUITINGphase readoutNCT06978777: Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity

Sponsor: University Hospital, Basel, Switzerland. Phase: NA. Conditions: Brown Adipose Tissue (BAT) Physiology, Cold Exposure

full page →ctgov ↗
›COMPLETEDphase readoutNCT07317375: Effectiveness of Stanley Paris Manual Therapy vs. Conventional Physiotherapy in Reducing Pain and Improving Function in Grade II Knee Osteoarthritis

Sponsor: Ibadat International University, Islamabad. Phase: NA. Conditions: Osteoarthritis (OA) of the Knee

full page →ctgov ↗
›RECRUITINGphase readoutNCT06823375: SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Sponsor: Chinese University of Hong Kong. Phase: PHASE2. Conditions: HCC

full page →ctgov ↗
›RECRUITINGphase readoutNCT07496957: Preserflo MicroShunt Versus Trabeculectomy

Sponsor: Medical University of Bialystok. Phase: NA. Conditions: GLAUCOMA 1, OPEN ANGLE, D (Disorder)

full page →ctgov ↗
›RECRUITINGphase readoutNCT02429557: Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

Sponsor: Vanderbilt University Medical Center. Phase: PHASE1. Conditions: Orthostatic Hypotension, Pure Autonomic Failure, Multiple System Atrophy, Autonomic Failure

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07551557: Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic Function

Sponsor: Jiangsu vcare pharmaceutical technology co., LTD. Phase: PHASE1. Conditions: Hepatic Impairment and Healthy Female

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06047457: A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

Sponsor: Ipsen. Phase: PHASE3. Conditions: Episodic Migraine

full page →ctgov ↗
›RECRUITINGphase readoutNCT07444112: Effect of Myofascial Release Therapy on University Students With Text Neck Syndrome.

Sponsor: University of Health Sciences Lahore. Phase: NA. Conditions: Text Neck Syndrome

full page →ctgov ↗
›RECRUITINGphase readoutNCT07006012: RGL-305+ Lymphoma + Exploratory Clinical Study

Sponsor: Fudan University. Phase: NA. Conditions: Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)

full page →ctgov ↗
← prev
page 61 of 158
next →